These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31470674)

  • 1. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
    Heeke S; Benzaquen J; Long-Mira E; Audelan B; Lespinet V; Bordone O; Lalvée S; Zahaf K; Poudenx M; Humbert O; Montaudié H; Dugourd PM; Chassang M; Passeron T; Delingette H; Marquette CH; Hofman V; Stenzinger A; Ilié M; Hofman P
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
    Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Kim H; Kwon HJ; Kim ES; Kwon S; Suh KJ; Kim SH; Kim YJ; Lee JS; Chung JH
    Cancer Res Treat; 2022 Apr; 54(2):424-433. PubMed ID: 34237208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.
    Heeke S; Benzaquen J; Hofman V; Long-Mira E; Lespinet V; Bordone O; Marquette CH; Delingette H; Ilié M; Hofman P
    J Thorac Oncol; 2020 Sep; 15(9):1535-1540. PubMed ID: 32450274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
    He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical utility of tumor mutational burden in non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
    Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
    Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age.
    Wu Y; Xu J; Xu J; Wang Y; Wang L; Lv W; Hu J
    Biomark Res; 2020; 8():9. PubMed ID: 32308981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
    Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
    Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
    Heeke S; Hofman P
    Transl Lung Cancer Res; 2018 Dec; 7(6):631-638. PubMed ID: 30505707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.
    Vokes NI; Liu D; Ricciuti B; Jimenez-Aguilar E; Rizvi H; Dietlein F; He MX; Margolis CA; Elmarakeby HA; Girshman J; Adeni A; Sanchez-Vega F; Schultz N; Dahlberg S; Zehir A; Jänne PA; Nishino M; Umeton R; Sholl LM; Van Allen EM; Hellmann MD; Awad MM
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31832578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
    Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
    Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.